Latest Oncology News

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

October 22nd 2021

Kristi Rosa

The frontline combination of trifluridine/tipiracil and bevacizumab was not found to result in a significant improvement in progression-free survival over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial.

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

October 22nd 2021

Kristi Rosa

The European Commission has approved pembrolizumab plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors have a PD-L1 expression combined positive score of 10 or higher and who have not previously received chemotherapy for metastatic disease.

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

October 22nd 2021

Kristi Rosa

The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

October 22nd 2021

The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.

Will Slow and Steady Progress in Treating SCLC Win the Race?

Will Slow and Steady Progress in Treating SCLC Win the Race?

October 22nd 2021

Christina T. Loguidice

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Latest Oncology Videos

All Oncology News

Rationale for Ovarian Suppression in HR+ Breast Cancer

March 5th 2021

Sara A. Hurvitz, MD, David Geffen School of Medicine

During a discussion regarding data demonstrated by the RxPONDER trial in HR-positive breast cancer, breast oncologists consider when ovarian suppression is most appropriate and for whom.

Results of RxPONDER in HR+ Breast Cancer

March 5th 2021

Sara A. Hurvitz, MD, David Geffen School of Medicine

Dr Andrew Seidman reacts to outcomes of the RxPONDER trial of chemotherapy use in women with HR-positive breast cancer at low risk of recurrence.

Understanding the CAR-T Process: Collection Through Infusion

March 5th 2021

Ian Flinn, MD, PhD, Sarah Cannon Research Institute

TACE and Systemic Therapy in HCC

March 5th 2021

Richard S. Finn, MD, UCLA Health

An in-depth discussion about the role of TACE in combination with systemic therapies for the treatment of HCC.

Recent Findings in Systemic Therapy for Patients With BCLC Stage B HCC 

March 5th 2021

Richard S. Finn, MD, UCLA Health

Amit G. Singal, MD, MS, leads a review of recent data around the outcomes of systemic therapy for patients with BCLC stage B HCC.

Dr. Brufsky on the Role of Neoadjuvant Chemotherapy in TNBC

March 5th 2021

Adam Brufsky,MD

Adam M. Brufsky, MD, PhD, discusses the role of neoadjuvant chemotherapy in triple-negative breast cancer.

Dr. Borgen on Eliminating Opioid Use in Breast Cancer

March 5th 2021

Patrick I. Borgen, MD

Patrick I. Borgen, MD, discusses eliminating the use of opioids in patients with breast cancer.

Dr. Till on the Potential to Utilize CAR T-Cell Therapy Earlier in MCL

March 4th 2021

Brian Till, MD

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.

Dr. Bociek on Reserving Allo-SCT for Certain Patients with CLL

March 4th 2021

R. Gregory Bociek, MD

R. Gregory Bociek, MD, discusses the rationale to reserve allogeneic stem cell transplant for certain patients with chronic lymphocytic leukemia.

Dr. Bekaii-Saab on the Toxicity Differences Between Regorafenib and TAS-102 in CRC

March 4th 2021

Tanios Bekaii-Saab, MD, FACP

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Poziotinib Shows Meaningful Activity in EGFR Exon 20–Mutant NSCLC

March 4th 2021

Kristi Rosa

Poziotinib, when given at a daily dose of 16 mg, was found to demonstrate clinically meaningful activity when used in treatment-naïve patients with metastatic non–small cell lung cancer who harbor EGFR exon 20 mutations.

Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

March 4th 2021

OncLive Staff

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

Ixazomib Triplets Show Efficacy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

March 4th 2021

Gina Mauro

Ixazomib-based triplet regimens as induction therapy elicited higher rates of efficacy compared with ixazomib/dexamethasone alone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma.

Dr. Levy on Future Research Directions for Lenvatinib in HCC

March 4th 2021

Anna T. Levy, DO

Anna T. Levy, DO, discuses future research directions for lenvatinib in patients with hepatocellular carcinoma.

New Indications in HER2+ Breast Cancer Spark Discussions on Selection, Safety, and Sequencing

March 4th 2021

Caroline Seymour

The KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB trials have changed practice for patients with HER2-positive breast cancer for the better.

See All News